Bayer submits rivaroxaban for Japanese approval

Kaitlyn Dmyterko | | Health Imaging | Diagnostic Imaging
Bayer Healthcare has submitted rivaroxaban (Xarelto), an oral anticoagulant, for marketing approval to the Japanese Ministry of Health, Labor and Welfare. The drug is indicated for the prevention of stroke in atrial fibrillation patients.

The marketing approval submission is based off of the positive results of the ROCKET AF study and Phase III J-ROCKET AF study, which both evaluated the use of rivaroxaban versus dose-adjusted warfarin in non-valvular AF patients at risk for stroke.

The 20 mg dose of the drug has already been submitted for marketing approval in the EU and the U.S.

Rivaroxaban, developed jointly by Bayer Healthcare and Johnson & Johnson, has a current market indication for venous thromboembolism in adult patients following elective knee or hip surgery.

Kaitlyn Dmyterko

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.